Fig. 4. Combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency.

A separate experiment was performed as described in Fig. 2A. At the end of treatment, BM cells from each group (1 × 10⁶, 0.5 × 10⁶, and 0.25 × 10⁶ cells/mouse) plus 0.2 × 10⁶ wild-type BM cells were transplanted into wild-type FBV/N recipient mice irradiated at 900 cGy (Fig. 2A, arm III). (A) PB leukemia burden at the end of treatments. (B) PB GFP⁺ cells obtained from mice 16 weeks after secondary transplant at 0.25 × 10⁶ cells/mouse (left, plotted as mean ± SEM and right as individual animals). (C) PB engrafted/total transplanted mice and LT-HSC frequency in mice transplanted with BM cells from each treatment group. (D) BM GFP⁺ cells and Bcr-Abl mRNA expression in BM cells in mice 16 weeks after secondary transplant at 0.25 × 10⁶ cells/mouse. CON, control.